Published in Proc Natl Acad Sci U S A on July 02, 2012
Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 1.36
RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One (2013) 1.14
The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol (2014) 1.05
Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. PLoS One (2013) 0.97
Dynamic protein interaction modules in human hepatocellular carcinoma progression. BMC Syst Biol (2013) 0.96
Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer (2014) 0.94
Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci (2013) 0.94
HBV induced HCC: major risk factors from genetic to molecular level. Biomed Res Int (2013) 0.92
Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol (2013) 0.89
Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation. Front Immunol (2014) 0.88
Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog (2013) 0.88
Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol (2015) 0.88
Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection. Sci Rep (2014) 0.88
Time for Integrating Clinical, Lifestyle and Molecular Data to Predict Drug Responses. EBioMedicine (2016) 0.87
The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis. J Biomed Sci (2014) 0.86
Negative impact of preoperative platelet-lymphocyte ratio on outcome after hepatic resection for intrahepatic cholangiocarcinoma. Medicine (Baltimore) (2015) 0.84
Chronic hepatitis B: role of anti-platelet therapy in inflammation control. Cell Mol Immunol (2015) 0.83
Platelets harness the immune response to drive liver cancer. Proc Natl Acad Sci U S A (2012) 0.83
Hepatitis B: future curative strategies. Curr Opin Infect Dis (2014) 0.81
Role of hemostatic factors in hepatic injury and disease: animal models de-liver. J Thromb Haemost (2016) 0.80
Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol (2014) 0.79
Effector CD8 T cell trafficking within the liver. Mol Immunol (2012) 0.79
Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase. Oncology (2013) 0.79
Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol (2016) 0.79
Hepatitis B Virus Pre-S2 Mutant Induces Aerobic Glycolysis through Mammalian Target of Rapamycin Signal Cascade. PLoS One (2015) 0.79
Experimental models of liver fibrosis. Arch Toxicol (2015) 0.78
Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. Semin Oncol (2014) 0.78
Immune-mediated Liver Injury in Hepatitis B Virus Infection. Immune Netw (2015) 0.78
Hepatic effector CD8(+) T-cell dynamics. Cell Mol Immunol (2014) 0.77
NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prev Res (Phila) (2015) 0.77
Spatiotemporal dynamics of effector CD8+ T cell responses within the liver. J Leukoc Biol (2015) 0.76
Prevention of chronic HBV infection induced hepatocellular carcinoma development by using antiplatelet drugs. Hepatobiliary Surg Nutr (2012) 0.76
Activation of ATP citrate lyase by mTOR signal induces disturbed lipid metabolism in hepatitis B virus pre-S2 mutant tumorigenesis. J Virol (2014) 0.76
Hepatocellular carcinoma: could antiplatelet drugs be used to prevent HBV-associated hepatocellular carcinoma? Nat Rev Gastroenterol Hepatol (2012) 0.75
Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment. BMC Infect Dis (2015) 0.75
Immune-Mediated Therapies for Liver Cancer. Genes (Basel) (2017) 0.75
The preoperative platelet-lymphocyte ratio versus neutrophil-lymphocyte ratio: which is better as a prognostic factor in oral squamous cell carcinoma? Ther Adv Med Oncol (2016) 0.75
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol (2016) 0.75
Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis. PLoS One (2016) 0.75
Platelet plays a role in the pathogenesis of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology (2013) 0.75
Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: a revolution in hepatocellular carcinoma prevention? Hepatology (2013) 0.75
Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget (2016) 0.75
Induction of apurinic endonuclease 1 overexpression by endoplasmic reticulum stress in hepatoma cells. Int J Mol Sci (2014) 0.75
Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B. PLoS One (2017) 0.75
Targeting Platelets for the Treatment of Cancer. Cancers (Basel) (2017) 0.75
Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol (2017) 0.75
Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer. Cell Death Dis (2017) 0.75
High seroprevalence of human herpesvirus type 8 in patients with hepatocellular carcinoma. Eur J Clin Microbiol Infect Dis (2014) 0.75
A Liver Index and its Relationship to Indices of HCC Aggressiveness. J Integr Oncol (2016) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med (2004) 10.91
The coagulopathy of chronic liver disease. N Engl J Med (2011) 5.63
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (1998) 5.21
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science (2002) 4.21
Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol (2006) 3.84
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 2.19
Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat (2009) 2.18
Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11
Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol (1994) 2.05
Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol (2004) 1.94
Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity (2003) 1.84
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol (2006) 1.73
MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest (2004) 1.65
Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res (2003) 1.55
Synergistic CD40 signaling on APCs and CD8 T cells drives efficient CD8 response and memory differentiation. J Leukoc Biol (2012) 1.53
Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A (2008) 1.48
A new role for an old molecule: serotonin as a mitogen. Am J Physiol (1997) 1.45
Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog (2011) 1.34
Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res (2003) 1.31
Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2002) 1.29
Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation (2001) 1.27
Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology (2010) 1.25
Liver biopsy findings in chronic hepatitis B. Hepatology (2009) 1.18
Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Ther (2005) 1.18
Platelet-lymphocyte cross-talk. J Leukoc Biol (2008) 1.18
The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther (2010) 1.14
Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer (2011) 1.12
The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta (2010) 1.12
Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation. J Hepatol (2012) 1.05
Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Clin Vaccine Immunol (2007) 1.04
Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood (1993) 1.02
Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B. Cancer Res (2004) 0.99
Do human platelets express COX-2? Prostaglandins Leukot Essent Fatty Acids (2001) 0.89
Ischemic preconditioning and intermittent clamping confer protection against ischemic injury in the cirrhotic mouse liver. Liver Transpl (2008) 0.87
DNA bases attack by reactive metabolites produced during carbon tetrachloride biotransformation and promotion of liver microsomal lipid peroxidation. Res Commun Mol Pathol Pharmacol (1997) 0.82
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature (2007) 4.88
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol (2006) 3.84
Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A (2005) 3.83
Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature (2010) 3.71
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest (2010) 3.10
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics (2005) 2.99
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
The autophagy machinery is required to initiate hepatitis C virus replication. Proc Natl Acad Sci U S A (2009) 2.91
Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med (2007) 2.85
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A (2002) 2.71
Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol (2006) 2.68
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest (2002) 2.65
Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A (2003) 2.64
Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A (2010) 2.46
Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe (2009) 2.33
Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proc Natl Acad Sci U S A (2007) 2.33
Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe (2012) 2.25
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 2.19
Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol (2005) 2.13
CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature (2009) 2.13
Acute thrombocytopenia after liver transplant: role of platelet activation, thrombopoietin deficiency and response to high dose intravenous IgG treatment. J Hepatol (2007) 2.09
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A (2006) 2.09
PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol (2007) 2.08
Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology (2008) 2.07
Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol (2002) 2.05
Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol (2006) 2.02
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A (2004) 1.96
Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood (2006) 1.95
Replication of a hepatitis C virus replicon clone in mouse cells. Virol J (2006) 1.90
Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology (2014) 1.89
Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. Proc Natl Acad Sci U S A (2006) 1.88
Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity (2005) 1.83
Systematic discovery of TLR signaling components delineates viral-sensing circuits. Cell (2011) 1.83
Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell (2008) 1.80
Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A (2009) 1.76
High shear-dependent loss of membrane integrity and defective platelet adhesion following disruption of the GPIbα-filamin interaction. Blood (2010) 1.75
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol (2006) 1.73
The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol (2009) 1.71
Chemokine guidance of central memory T cells is critical for antiviral recall responses in lymph nodes. Cell (2012) 1.70
B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. Immunity (2012) 1.70
In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood (2007) 1.69
Viruses and the autophagy machinery. Cell Cycle (2010) 1.68
Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol (2002) 1.66
MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest (2004) 1.65
CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion. PLoS Pathog (2013) 1.65
Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha. Science (2003) 1.65
Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol (2010) 1.64
Immune tolerance split between hepatitis B virus precore and core proteins. J Virol (2005) 1.63
The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A (2006) 1.62
Nkx2-5(+)islet1(+) mesenchymal precursors generate distinct spleen stromal cell subsets and participate in restoring stromal network integrity. Immunity (2013) 1.62
A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A (2004) 1.61
Bone marrow as an alternative site for islet transplantation. Blood (2009) 1.61
Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol (2002) 1.61
Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol (2002) 1.58
Distinct spatio-temporal Ca2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow. Blood (2009) 1.57
The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood (2003) 1.56
Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol (2002) 1.56
A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med (2003) 1.56
Role for ADAP in shear flow-induced platelet mechanotransduction. Blood (2009) 1.55
Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. Blood (2004) 1.55
Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging (2012) 1.53
Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci U S A (2001) 1.51
Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets. Proc Natl Acad Sci U S A (2005) 1.51
Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice. Proc Natl Acad Sci U S A (2002) 1.51
Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A (2008) 1.48
A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2008) 1.48
Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol (2006) 1.47
Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A (2005) 1.47
Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care (2007) 1.45
Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol Cell (2006) 1.44
Right isthmus ablation reduces supraventricular arrhythmias after surgery for chronic atrial fibrillation. Ann Thorac Surg (2008) 1.44
Defective Th1 cytokine gene transcription in CD4+ and CD8+ T cells from Wiskott-Aldrich syndrome patients. J Immunol (2006) 1.44
Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. Chem Biol (2011) 1.41
Should we discontinue intraaortic balloon during cardioplegic arrest? Splanchnic function results of a prospective randomized trial. Ann Thorac Surg (2005) 1.41
Hospital outcome analysis after different techniques of left internal mammary grafts harvesting. Ann Thorac Surg (2007) 1.40
Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol (2003) 1.39